The global post-operative cataract surgery inflammation treatment market is slated to reach a valuation of USD 4.56 billion in 2023. According to Future Market Insights, the market is expected to grow at a 6.77% CAGR until 2033, valued at USD 8.78 billion.
Post-operative cataract surgeries are driven mainly by the aging population and the increased prevalence of ocular disorders resulting in higher demand for cataract surgery devices.
The increasing demand in the global cataract market is a replication of the growing elderly population, as people aged over 60 years frequently develop conditions in which eyes have reduced elasticity, and in turn, it affects normal functioning. This boosts market growth.
The rise in the number of cortical necrosis therapeutics being delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
The lack of qualified personnel who are unable to treat the patients with appropriate treatments could curb the growth of the global cataracts market over a forecast period.
The huge expenditure associated with the treatment of cataracts surely hampers market growth. The high cost of cataract surgery, mainly in developing countries such as India, Brazil, South Africa, and China restrains the global market.
| Attributes | Details |
|---|---|
| Base year Market Value (2022) | USD 4.045 billion |
| Projected Forecast Value (2023) | USD 4.56 billion |
| Projected Forecast Value (2033) | USD 8.78 billion |
| Growth rate | 6.77% |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global post-operative cataract surgery inflammation treatment grew at a CAGR of 6.45% from 2018 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence.
Historically, the choice of intraocular lenses (IOLs) is a field that has seen great improvement. Optical biometers were then available and had become more affordable, providing more accurate measurements than those provided by ultrasonography, by reaching optimal accuracy even in dense and advanced cataracts.
Also, artificial intelligence was used for enhancing the precision of IOL calculations and personalized approaches for both patients and surgeons. Postoperative adjustment of IOL power had become available with the introduction of novel IOL technologies.
The progress in evaluating the anterior surface and the tear apparatus has shown that tear dysfunction can significantly affect surgical outcomes, including producing a less precise IOL calculation and a longer postoperative recovery.
But nowadays, the current study is the first to compare intracanalicular dexamethasone directly to topical steroids after cataract surgery. Importantly, the study showed that the safety and efficacy of the two approaches were similar.
The rates of breakthrough inflammation reported for both groups were similar to those reported by previous studies where more than half of the patients experiencing breakthrough inflammation admitted poor compliance or anxiety over administering drops.
Although, the investigators of the current study have noted that patients should be counseled on possible epiphora in the postoperative period where two of 24 patients have been experiencing canalicular obstruction with an intracanalicular dexamethasone ophthalmic insert.
Rising prevalence of ophthalmic disorders & ocular pains
Ophthalmic disorders are the vital cause of major ocular and orbital pains in the eye. Ocular pain occurs over the surface of the eyes along with symptoms such as scratching, burning, or itching sensation.
This may be due to multiple reasons, including irritation from foreign objects, infection, or trauma. Eyelashes or pieces of dirt, smoke, dust, or some harsh eye cosmetics are the common causes leading to ocular pain, redness, and watery eyes.
The prevalence of ocular pain keeps showing a surge in growth as chemical industries and pollution around the world are growing. Chemical burns and flash burns cause significant and severe ocular pain due to irritations over the eye surface. Style and blepharitis lead to severe ocular pain as they cause eye and oil glands to be more sensitive around the area.
A rise in traumatic injuries
Traumatic head injury is one of the causes of such disorders as optic nerve disorders. A traumatic injury is a physical injury that occurs suddenly with a certain degree of severity. Trauma can be caused by a variety of external injuries.
The most common causes of traumatic injury include road accidents, sports injuries, and violence, among others which can lead to some serious eye disorders as well. The prevalence of such traumatic injuries is highly seen worldwide.
Hence, such traumatic injuries lead to optic nerve disorders, which are affecting the population in these years and it is increasing with the rising population. Therefore, a rise in traumatic injuries is expected to drive market growth.
Principal Consultant
High cost & risks associated with eye surgery & treatment
The cost of the various disorders treatment plays a major role in the market. The optic nerve disorders treatments are highly sophisticated, as the prevalence of such disorders is increasing; hence the need for such products has eventually raised, thereby raising the treatment cost, which can hinder the market growth in the coming years.
There are various methods for the treatment of optic neuritis disorder. Some of them are patients can take various medicines such as corticosteroids like methylprednisolone, prednisone, immunoglobulin, vitamin B12 shots, and various other surgeries. With these, there are some risks associated with it.
Therefore, for some of the population around the country, it is difficult for them to undergo such treatments due to the high cost. Hence, the high cost associated with ophthalmic disorders treatment is expected to restrain the market growth.
Lack of skilled professionals
The number of ophthalmologists in both emerging and industrialized countries is minor. However, projections are a little higher for developing countries. The number of ophthalmologists is cumulative but not as fast as the population of elderly patients aged 60 years or older who need to be amplified ophthalmologic care.
In most countries, the problem is that demographic changes do not match up with professional development. It is required to train eye care teams to meet the current number of ophthalmologists worldwide. The increased need for ophthalmologists globally also reflects an increase in the cases of diabetes.
Diabetic patients should get their eyes inspected every year. The increasing demand for ophthalmologists is directly proportional to the growing geriatric population since eye care is an integral part of healthcare. The access to care gaps can be met by combining factors, including more efficient practice structures, processes, and appropriate use of technology.
Growth in the number of surgical procedures
The United States is expected to hold a major share of the market in North America. The major factors bolstering the market's growth are the growing number of surgical procedures, surge in awareness regarding postoperative pain management drugs, increasing number of product approvals, and rising focus on palliative care.
A research study titled "Comparison of Postoperative Pain Management Outcomes in the United States” was published stating that the American Pain Society Patient Outcome Questionnaire-Revised (APS-POQ-R) was completed by 244 patients in the United States with similar surgery sites. The Pain Management Index (PMI) was calculated on their first postoperative day.
Patients in the United States had a higher score on the APS-POQ "perception of pain management" subscale and a larger proportion of acceptable treatment, as assessed by the PMI.
Also, higher compliance with pain management recommendations has resulted in higher perceptions among patients. Such statistics are likely to increase the demand for postoperative pain management medications within the country, thereby boosting the market's growth.
Several market players are engaged in implementing strategic initiatives, thereby contributing to the market's growth.
In May 2021, Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform postsurgical pain management and recovery, reported the first-ever clinical data showing non-opioid pain relief lasting two weeks after a single administration and Heron.
Therapeutics, Inc., a commercial-stage biotechnology company focused on developing treatments to address some of the most important unmet patient needs, reported that the United States Food and Drug Administration (FDA) has approved ZYNRELEF (bupivacaine and meloxicam) extended-release solution for use in adults for soft tissue or periarticular instillation to produce postsurgical analgesia for up to 72 hours after a bunionectomy, open inguinal herniorrhaphy, and total knee arthroplasty.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Bromfenac drug gains the dominant market share
Bromfenac ophthalmic solution 0.09% is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction.
This is so because, the efficacy and safety of sodium bromfenac eye drop in the treatment of postoperative inflammation of cataract surgery were evaluated by the effective rate, symptom score, adverse reactions, incidence, recurrence rate, etc.
Injections are expected to boost the market share
Intracameral dexamethasone injection in the treatment of cataract surgery-induced inflammation.
Topical ophthalmic drug delivery represents the most popular option among cataract surgeons due to its effectiveness and good safety profile in controlling inflammation after cataract surgery.
Some of the prominent players in the post-operative cataract surgery inflammation drug treatment market are
Some of the important developments of the key players in the market are
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 6.77% from 2023 to 2033 |
| Market value in 2023 | USD 4.56 Billion |
| Market value in 2033 | USD 8.78 Billion |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | USD Billion for Value and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug class, Route of Administration, Distribution Channel, Region |
| Regions Covered |
North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Companies Profiled | Mallinckrodt Pharmaceuticals; Salix Pharmaceuticals; GlaxoSmithKline plc.; Pfizer Inc.; ASKA Pharmaceutical Co., Ltd.; Bausch Health; Johnson & Johnson Services, Inc.; Janssen Global Services; Takeda Pharmaceutical Company Limited; Merck & Co., Inc. |
| Customization Scope | Available on Request |
The market is estimated to secure a valuation of USD 4.56 billion in 2023.
The market is estimated to reach USD 8.78 billion by 2033.
Through 2033, the market is anticipated to expand at a 6.77% CAGR.
The market share for Injections segment is going to be the leading segment
The bromfenac segment to be the leading segment in the market.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Bromfenac 5.2. Indomethacin 5.3. Diclofenac 5.4. Flurbiprofen 5.5. Nepafenac 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Oral 6.2. Injectable 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Hospital Pharmacy 7.2. Online Pharmacy 7.3. Retail Pharmacy 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. MEA 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Mallinckrodt Pharmaceuticals 18.2. Salix Pharmaceuticals 18.3. GlaxoSmithKline plc. 18.4. Pfizer Inc. 18.5. ASKA Pharmaceutical Co., Ltd. 18.6. Bausch Health 18.7. Johnson & Johnson Services, Inc. 18.8. Janssen Global Services 18.9. Takeda Pharmaceutical Company Limited 18.10. Merck & Co., Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Post-Operative Cataract Surgery Inflammation Treatment Market
